Island submits key US FDA meeting request for new antiviral asset Galidesivir

Island submits key US FDA meeting request for new antiviral asset Galidesivir

Island submits Type C meeting request with US FDA on new asset Galidesivir Biotech seeks alignment on use of FDA animal rule to fast-track Galidesivir for Marburg virus Meeting with FDA expected in Q4 CY25 as animal study remains on track to start and complete next quarter   Special Report: Australian antiviral drug development company Island Pharmaceuticals has formally lodged a request for a Type C meeting for Galidesivir with the US Food and …